Research advances on the mechanisms for Candida albicans resistance to antifungal azole

doi:10.3969/j.issn.1673-8640.2014.09.025

Abstract

Abstract: Candida albicans is the most important opportunistic pathogenic yeast in clinic. With the widespread use of antifungal agents, the chance of antifungal resistance in Candida albicans is increasing. The emergence of resistance is an difficult point for drug treatment. Mutation or overexpression in drug target enzymes, overexpression of multidrug transporters, cellular stress responses, formation of biofilm and so on, compose the major molecular mechanisms which contribute to the development of antifungal azole resistance in Candida albicans. This paper gives a general review of the azole resistance mechanisms in Candida albians.

Key words: Candida albicans, Azole, Resistance mechanism, Target enzyme, Multidrug transporter, Biofilm

CLC Number:

R446.5

WEI Bing, LIU Jinyan, SHI Ce, XIANG Mingjie. Research advances on the mechanisms for Candida albicans resistance to antifungal azole[J]. , 2014, 29(9): 978-981.

References

[1] Perea S, Patterson TF. Antifungal resistance in pathogenic fungi [J].Clin Infect Dis, 2002,35(9):1073-1080.
[2] 曹先伟,冀朝辉,万喆,等.白念珠菌耐药株CYP 51基因突变热点探讨[J].中华医院感染学杂志, 2004, 14(11):1215-1218.
[3] White TC. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans[J].Antimicrob Agents Chemother, 1997,41(7): 1488-1494.
[4] Müller TC, Rocha JB, Morsch VM, et al. Antidepressants inhibit human acetylcholinesterase and butyrylcholinesterase activity[J].Biochim Biophys Acta, 2002,1587(1): 92-98.
[5] Kontoyiannis DP,Sagar N,Hirschi KD.Overexpression of Erg11 p by the regulatable GAL1 promoter confers fluconazole resistance in Saccharomyces cerevisiae[J]. Antimicrob Agents Chemother, 1999, 43(11): 2798-2800.
[6] MacPherson S, Akache B, Weber S, et al.Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes[J].Antimicrob Agents Chemother, 2005,49(5):1745-1752.
[7] Hoehamer CF, Cummings ED, Hilliard GM, et al. Upc2p-associated differential protein expression in Candida albicans[J].Proteomics, 2009, 9(20):4726-4730.
[8] Heilmann CJ, Schneider S, Barker KS, et al. An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans[J].Antimicrob Agents Chemother,2010,54(1):353-359.
[9] Lyons CN, White TC.Transcriptional analyses of antifungal drug resistance in Candida albicans[J].Antimicrob Agents Chemother, 2000,44(9):2296-2303.
[10] Cowen LE, Kohn LM, Anderson JB. Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans[J].J Bacteriol, 2001,183(10):2971-2978.
[11] Coste A,Selmecki A,Forche A,et al.Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates[J].Eukaryot Cell,2007,6(10):1889-1904.
[12] Coste A, Turner V, Ischer F,et al.A mutation in Tac1p,a trainscription factor regulating CDR1 and CDR2,is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans[J].Genetics,2006,172(4):2139-2156.
[13] Coste AT, Crittin J, Bauser C, et al. Functional analysis of cis- and trans- acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system[J].Eukaryot Cell, 2009, 8(8):1250-1267.
[14] Morschhuser J.Regulation of multidrug resistance in pathogenic fungi[J]. Fungal Genet Biol,2010,47(2):94-106.
[15] Talibi D, Raymond M. Isolation of a putative Candida albicans transcriptional regulator involved in pleiotropic drug resistance by functional complementation of a pdr1 pdr3 mutation in Saccharomyces cerevisiae[J].J Bacteriol, 1999,181(1):231-240.
[16] Schubert S, Rogers PD, Morschhuser J.Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains[J]. Antimicrob Agents Chemother, 2008, 52(12):4274-4280.
[17] Dunkel N, Blass J, Rogers PD, et al. Mutations in the multi-drug resistance regulator MRR1,followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains[J]. Mol Microbiol, 2008, 69(4):827-840.
[18] Liu TT, Znaidi S, Barker KS, et al. Genome-wide expression and location analyses of the Candida albicans Tac1p regulon[J].Eukaryot Cell, 2007, 6(11):2122-2138.
[19] Karababa M, Valentino E, Pardini G, et al. CRZ1, a target of the calcineurin pathway in Candida albicans[J].Mol Microbiol, 2006, 59(5):1429-1451.
[20] Nett JE, Sanchez H, Cain MT, et al. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan [J]. J Infect Dis, 2010, 202(1):171-175.
[21] Khot PD, Suci PA, Miller RL, et al. A small subpopulation of blastospores in Candida albicans biofilms exhibit resistance to amphotericin B associated with differential regulation of ergosterol and beta-1, 6-glucan pathway genes [J]. Antimicrob Agents Chemother, 2006, 50(11): 3708-3716.
[22] Lepak A, Nett J, Lincoln L, et al. Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole [J]. Antimicrob Agents Chemother, 2006, 50(4):1311-1319.
[23] García-Snchez S, Aubert S, Iraqui I, et al. Candida albicans biofilms: a developmental state associated with specific and stable gene expression patterns [J]. Eukaryot Cell, 2004, 3(2): 536-545.
[24] 赵亮,陈贻锴. 生物膜结构对白色念珠菌的耐药性的影响[J]. 医学综述,2007, 13 (12): 889-891.